Detalhe da pesquisa
1.
Discovery and optimization of novel pyridines as highly potent and selective glycogen synthase kinase 3 inhibitors.
Bioorg Med Chem Lett
; 30(4): 126930, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31926786
2.
Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.
Mol Pharmacol
; 82(5): 843-59, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22859723
3.
Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease.
Neuron
; 110(22): 3711-3726.e16, 2022 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087583
4.
Structural and Mechanistic Regulation of the Pro-degenerative NAD Hydrolase SARM1.
Cell Rep
; 32(5): 107999, 2020 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32755591
5.
Enantioselective linchpin catalysis by SOMO catalysis: an approach to the asymmetric alpha-chlorination of aldehydes and terminal epoxide formation.
Angew Chem Int Ed Engl
; 48(28): 5121-4, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19526479
6.
Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere.
J Med Chem
; 62(22): 10258-10271, 2019 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31736296
7.
Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.
ACS Med Chem Lett
; 9(7): 757-760, 2018 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30034614
8.
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.
Cancer Discov
; 8(12): 1598-1613, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30254092
9.
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.
Cancer Discov
; 8(12): 1582-1597, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30254093
10.
Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.
J Med Chem
; 60(20): 8482-8514, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29016121
11.
Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.
ACS Med Chem Lett
; 5(4): 384-9, 2014 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900845
12.
Optimization of GPR40 Agonists for Type 2 Diabetes.
ACS Med Chem Lett
; 5(5): 517-21, 2014 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900872
13.
Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
ACS Med Chem Lett
; 4(6): 551-5, 2013 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900707
14.
Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
ACS Med Chem Lett
; 3(9): 726-30, 2012 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900539
15.
A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
PLoS One
; 7(10): e46300, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23056280
16.
The direct and enantioselective organocatalytic alpha-oxidation of aldehydes.
J Am Chem Soc
; 125(36): 10808-9, 2003 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-12952459
17.
The first enantioselective organocatalytic Mukaiyama-Michael reaction: a direct method for the synthesis of enantioenriched gamma-butenolide architecture.
J Am Chem Soc
; 125(5): 1192-4, 2003 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-12553821
18.
Direct and enantioselective organocatalytic alpha-chlorination of aldehydes.
J Am Chem Soc
; 126(13): 4108-9, 2004 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-15053591